Continuous opioid treatment for chronic noncancer pain: A time for moderation in prescribing

Postgraduate Medicine

Volumn 121, Issue 4, 2009, Pages 61-66

  Colameco, Stephen ^a,b   Coren, Joshua S ^a   Ciervo, Carman A ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b Bldg D ^*  (United States)

Author keywords

Opioids; Pain; Side effects

Indexed keywords

FENTANYL; METHADONE; MORPHINE; OPIATE; OXYCODONE; PRASTERONE;

ANALGESIC ACTIVITY; CHRONIC PAIN; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERANCE; ENDOCRINE DISEASE; HUMAN; HYPERALGESIA; LONG TERM CARE; PRESCRIPTION; REVIEW; RISK;

ANALGESICS, OPIOID; DRUG UTILIZATION; HUMANS; OPIOID-RELATED DISORDERS; PAIN; RISK ASSESSMENT;

EID: 68149167716     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.07.2032     Document Type: Review

References (48)

1. Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA. 2007;97(3):249-251.
2. ACROS: Automation of Reports and Consolidated Orders System, U.S. Department of Justice Drug Administration. http:www.deadiversion.usdoj.gov/ arcos/index.html. Accessed June 30, 2009.
3. Paulozzi LJ, Ryan GW. Opioid analgesics and the rates of fatal drug poisoning in the United States. Am J Prev Med. 2006;31(6): 506-511.
4. Hall AJ, Logan JE, Toblin RI, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300(22):2613-2620.
5. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15(9): 618-627.
6. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11(2 suppl):S105-S120.
7. Washington State Agency Medical Directors' Group. Interagency guideline on opioid dosing for chronic non-cancer pain: an educational pilot to improse care and safety with opioid treatment. Olympia, WA: Washington State Department of Labor and Industries; 2007.
8. Veterans Health Administration, Department of Defense. VA/DoD clinical practice guideline for the management of opioid therapy for chronic pain. Washington DC: Veterans Health Administration, Department of Defense; 2003.
9. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage. 2003;26(5):1026-1048.
10. Chou R. Huffman LH; American Pain Society; American College of Physicians. Medications for acute and chronic lose back pain: a review of the evidence for an American Pain Society-American College of Physicians clinical practice guideline. Ann Intern Med. 2007;147(7):505-514.
11. Rowbotham MC, Lindsey CD. How effective long-term opioid therapy for chronic noncancer pain? Clin J Pain. 2007;23(4):300-302.
12. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage. 2008;35(2):214-228.
13. Højsted J, Sjøgren P. An update on the role of opioids in the management of chronic pain of nonmalignant origin. Curr Opin Anaesthesiol. 2007;20(5):451-455.
14. Eriksen J, Sjøgren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain. 2006;125(1-2):172-179.
15. Højsted J, Sjøgren P. An update on the role of opioids in the management of chronic pain of nonmalignant origin. Curr Opin Anaesthesiol. 2007;20(5):451-455.
16. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):147-159.
17. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
18. DuPen A, Shen D, Ersek M. Mechanisms of opioid-induced tolerance and hyperalgesia. Pain Manag Nurs. 2007;8(3):117-121.
19. Mitra S. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J Opioid Man. 2008;4(3):123-130.
20. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain. 2002;100(3):213-217.
21. Fine PG. Opioid insights: opioid-induced hyperalgesia and opioid rotation. J Pain Palliat Care Pharmacother. 2004;18(3):75-79.
22. Xu XJ, Colpaert F, Wiesenfeld-Hallin Z. Opioid hyperalgesia and tolerance versus 5-HT1A receptor-mediated inverse tolerance. Trends Pharmacol Sci. 2003;24(12):634-639.
23. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain. 2008;24(6):479-496.
24. Baron MJ, McDonald PW. Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag. 2006;2(5):277-282.
25. Rajagopal A. Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100(4):851-858.
26. Daniell HW. DHEAS defiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production. J Pain. 2006;7(12):901-907.
27. Kalyani RR, Gavini S, Dobs AS. Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am. 2007;36:333-348.
28. Colameco S, Coren JS, Zimmerman DJ. Buprenorphine-induced symptomatic hypogonadism in men: case reports and discussion. J Addict Med. 2008;2(3):147-150.
29. Mazer N, Chapman C, Daniell H, Volinn E. Opiods in non-cancer pain: Opioid Induced Androgen Deficiency in Men (OPIAD): an estimate of the potential patient population the U.S. and Canada. J Pain. 2004;5(3 suppl 1):S73
30. American Association of Clinical Endocrinologists. Medical Guidelines for the evaluation and treatment of hypogonadism in adult males. Endocr Pract. 2002;8(6):439-455.
31. Daniell HW. Sex hormone deficiency in depressed patients receiving opioids. Arch Intern Med. 2004;164(7):804.
32. Daniell HW. Opioid endrocinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9(1):28-36.
33. Daniell HW. Opioid-induced androgen deficiency discussion in opioid contracts. Am J Med. 2007:120(9):e21.
34. Cicero TJ, Surratt H, Inciardi JA, Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf. 2007;16(8):827-840.
35. Under the Counter: The Diversion and Abuse of Controlled Prescription Drugs in the U.S. The National Center on Addiction and Substance Abuse at Columbia University; 2005. http://www.casacolumbia.org/absolutenm/articlefiles/ 380-Under%20the%20Counter%20-20%Diversion.pdf Accessed June 17, 2009.
36. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res. 2006;6:46. http://www.biomedcentral.com/1472-6963/6/46. Accessed June 17, 2009.
37. Michna K, Jamison RN, Pham LD, et al. Urine toxicology screening among chronic pain patients on opioid theraphy: frequency and predictability of abnormal findings. Clin J Pain. 2007;23(2): 173-179.
38. Fleming MF, Davis J, Passik SD. Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients. Pain Med. 2008;9(8):1098-1106.
39. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9(4):444-459.
40. Federation of State Medical Boards: Model policy for the use of controlled substances for the treatment of pain. J Pain Palliat Care Pharmacother. 2004;19:73-78.
41. Sansone RA, Pole M, Dakroub H, Butler M. Childhood trauma, borderline personality symptomatology, and psychophysiological and pain disorders in adulthood. Psychosomatics. 2006;47(2):158-162.
42. Fishbain DA, Goldberg M, Meagher BR, Steele R, Rosomoff H. Male and female chronic pain patients categorized by DSM-III psychiatric diagnostic criteria. Pain. 1986;26(2):181-197.
43. Butler SF, Budman SH, Fernandez KC, et al. Cross validation of a screener to predict opioid misuse in chronic pain patients (SOAPP-R). J Addict Med. 2009;3(2):66-73.
44. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432-442.
45. Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7(9):671-681.
46. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Mandatory Guidelines for Federal Workplace Drug Testing Programs. Federal Register. 2004;69:19644-19673.
47. Jaffee WB, Trucco K, Teter C, Levy S, Weiss RD. Focus on alcohol and drug abuse: ensuring validity in urine drug testing. Psychiatr Serv. 2008;59(2):140-142.
48. Institute for Clinical Systems Improvement (ICSI). Assessment and management of chronic pain. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2008. http://www.guideline.gov/summary/summary.aspx?doc-id= 12998. Accessed June 17, 2009.